New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
September 21, 2024 04:10 ET
|
Teva Pharmaceutical Industries Ltd
As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and...
iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
September 20, 2024 16:05 ET
|
iBio, Inc.
SAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended...
Transaction in Own Shares
September 20, 2024 12:36 ET
|
Shell plc
Transaction in Own Shares 20 September, 2024 • • • • • • • • • • • • • • • • Shell plc (the ‘Company’) announces that on 20 September 2024 it purchased the following number of Shares for...
Weekly Report (September 13-19, 2024) Third Tranche of Stellantis 2024 Share Buyback Program
September 20, 2024 11:49 ET
|
STELLANTIS N.V
Weekly Report (September 13-19, 2024) Third Tranche of Stellantis 2024 Share Buyback Program AMSTERDAM, September 20, 2024 - Stellantis N.V. (“Stellantis” or the “Company”) announced today that...